Back to results
US 12,565,685 B2Granted
Engineering AAV
AssigneeSangamo Therapeutics, Inc.
InventorsKyle McGovern, David S. Ojala
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.
Claims20
A capsid protein comprising at least 4 contiguous amino acids of an amino acid sequence set forth in any of SEQ ID NO:
- 1-32 or at least 4 contiguous amino acids of an amino acid sequence set forth in any of SEQ ID NO:
- 68-110.
Dependencies are inferred from the claim text.